Obesity and related metabolic disorders are among the most pressing global health challenges, driving a surge in innovative therapies such as incretin receptor agonists and glucagon-like peptide-1 (GLP-1). GLP-1 therapies are driving unprecedented growth in obesity treatment, with expanding indications beyond weight loss into cardiovascular risk reduction, metabolic dysfunction-associated steatohepatitis (MASH), and sleep apnea. Rapid pipeline innovation, including oral formulations and combination therapies, create new opportunities and trial complexities.
Labcorp brings deep expertise in the science, operations, and patient dynamics of weight management trials—using biomarker‑driven solutions to translate complexity into actionable insights.
Scientific rigor and operational strength, multi-system biomarker expertise and global central lab infrastructure with experience across 47 studies, 32,000+ patients and 40 countries worldwide from 2020-2024.
Multi‑system testing, high-quality data and long‑term outcomes support to advance therapies for endocrine, lipid, musculoskeletal and body composition disorders
Hybrid and decentralized models, Labcorp patient service centers, data-driven patient identification and simplified long‑term safety testing for improved participation
Labcorp offers an extensive portfolio of safety, metabolic, hormonal, cardiovascular, inflammatory, and specialty biomarkers—along with nutritional and genetic assessments—to support weight management drug development across all phases of clinical research.
Group | Biomarkers |
Pre-diabetes/diabetes metabolic markers | Fasting insulin, fasting glucose, HOMA-IR, QUICKI, C-peptide, HbA1c, fructosamine, branched-chain amino acids |
Lipids | Lipid profile (total cholesterol, triglycerides, LDL, VLDL, HDL, non-HDL cholesterol), free fatty acids, ApoB, ApoC3, ApoC1, Lp(a), NMR lipoprotein profiling, LP-Insulin Resistance (LP-IR) test |
Cardiovascular risk markers | NT-proBNP, cardiac and non-cardiac hsCRP, cardiac hsTnT, hsTnI, hsCRP, CK, CK-MB |
| Muscle metabolism markers | sCystatin C, sCreatinine |
Renal markers | eGFR, microalbumin, uCreatinine, UACR, UPCR |
Liver function and injury | Total bilirubin, direct bilirubin, ALP, ALT, AST, GGT, lipase, amylase |
Circulating hormones, incretins, adipokines | Adiponectin, estradiol, glucagon, GLP-1, leptin, ghrelin, resistin, corticosterone, cortisol, testosterone, T3, T4, thyroid stimulating hormone (TSH), growth hormone (GH), DPP4, insulin growth factor-1 (IGF-1), calcitonin, estradiol, luteinizing hormone (LH), follicle stimulating hormone (FSH) |
Myokines and skeletal muscle turnover biomarkers | BDNF, GDF-11, GDF-15, follistatin and IGF-1 |
Nutritional status | Vitamins A, B1, B6, B12, D, E, K, folate, magnesium, ferritin and total iron, calcitriol |
| Inflammation cytokines | Proinflammatory cytokine panel, TNFα, IL-1β, IL-6, IFNγ, TGFβ1, PAI-1, TLR2, TLR4, NFKβ, IL-18 |
Bone homeostasis/mass | BSAP, osteocalcin, P1NP, CTX-1, TRAC5b, BALP, NTX |
Fibrosis markers | FIB-4, ELFTM score (PIIINP, TIMP-1 and HA), FGF-19, FGF-20, PRO-C3, PRO-C6, NIS4® and NIS2+® (using YKL-40) |
Microbiome transcriptomics | 16S Seq/fecal, saliva |
See how Labcorp's holistic approach to cardiometabolic clinical trials services can improve study design, uncover shared biomarkers and accelerate development.
Advance cardiovascular development with expert insights on biomarker strategies that streamline cardiovascular clinical trials and support novel treatments for heart disease.
Accelerate your MASLD and MASH drug development with Labcorp’s biomarker-driven strategies and comprehensive central lab solutions.
Advance your renal disease drug development efforts with expert biomarker strategies supporting the entire spectrum of kidney disease research.
From early-phase biomarker validation to global trial execution, Labcorp Central Laboratory Services provides the scientific depth and operational scale to help you bring your next breakthrough therapy to market.
